Showing results (71-80 of 4,632) with videos related to

Sort By:
Pageof 464
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|April 1, 1996
Bone marrow dosimetry: regional variability of marrow-localizing antibodyG Sgouros, I M Jureidini, A M Scott, et al.
Blood|December 1, 1994
Early mortality and the retinoic acid syndrome in acute promyelocytic leukemia: impact of leukocytosis, low-dose chemotherapy, PMN/RAR-alpha isoform, and CD13 expression in patients treated with all-trans retinoic acidL Vahdat, P Maslak, W H Miller, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 26, 1998
Humanized M195 monoclonal antibody conjugated to recombinant gelonin: an anti-CD33 immunotoxin with antileukemic activityL C Pagliaro, B Liu, R Munker, et al.
Developmental Pharmacology and Therapeutics|January 1, 1981
Ascorbic acid treatment in nephropathic cystinosis in identical twinsS E Oberfield, L S Levine, D Wellner, et al.
Molecular Immunology|August 1, 1995
Impact of the high tyrosine fraction in complementarity determining regions: measured and predicted effects of radioiodination on IgG immunoreactivityT K Nikula, M Bocchia, M J Curcio, et al.
Nuclear Medicine and Biology|April 1, 1995
A rapid, single vessel method for preparation of clinical grade ligand conjugated monoclonal antibodiesT K Nikula, M J Curcio, M W Brechbiel, et al.
Transactions - American Society for Artificial Internal Organs|January 1, 1976
Essential amino acid metabolism in maintenance dialysis patientsJ Chami, M Reidenberg, D Wellner, et al.
Molecular Immunology|October 1, 1993
Genetically engineered deglycosylation of the variable domain increases the affinity of an anti-CD33 monoclonal antibodyM S Co, D A Scheinberg, N M Avdalovic, et al.
Leukemia|January 1, 1996
Granulocyte colony-stimulating factor following chemotherapy in elderly patients with newly diagnosed acute myelogenous leukemiaP G Maslak, M A Weiss, E Berman, et al.
Leukemia|September 20, 2000
Consolidation therapy with high-dose cyclophosphamide improves the quality of response in patients with chronic lymphocytic leukemia treated with fludarabine as induction therapyM A Weiss, M Glenn, P Maslak, et al.
Pageof 464